

purifying said harvested virus under non-denaturing conditions to produce a purified virus substantially free from cellullarrand serum components;

inactivating said purified virus with an inactivating agent to provide a non-infectious, non-immunopotentiating and immunogenic RS viral preparation [virus], and

formulating said non-infectious, non-immunopotentiating and immunogenic RS viral preparation [virus] as said immunogenic composition.

12. (Amended) The method of claim 5 wherein said purifying step is effected by microfiltration to remove cell debris, tangential flow ultrafiltration to remove serum components and provide a retentate, pelleting the retentate [ultrafiltered material] by ultracentrifugation to further remove serum components, and subjecting the pelleted material to sucrose density gradient centrifugation.

Cancel claims 17 to 19.

REMARKS

Petition is hereby made under the provisions of 37 CFR 1.136(a) for an extension of three months of the period for response to the outstanding Office Action on this case. We enclose our cheque in the amount of the prescribed fees.

The Examiner indicated that restriction to a single invention was required and that claims 17 to 19 were withdrawn from further consideration by the Examiner as being drawn to a non-elected invention. These claims now have been deleted from this application. It is noted that claims 17 to 19 are being pursued in co-pending application 08/472,174. The claims of this application are now limited to the invention of Group I identified in the Office Action.

The Examiner noted that the PTO-1449 had a note attached that copies of the references were to follow, but that no such reference copies had been received. The Examiner had, however, considered the references which were of record